Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Frontline Brentuximab Vedotin Plus Chemotherapy Improves 6-Year Survival in Hodgkin Lymphoma

June 3rd 2022

Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine demonstrated a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, with a manageable safety profile consistent with prior findings in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

Sugemalimab Shows Promise for Natural Killer/T-cell Lymphoma

June 3rd 2022

Treatment with the anti–PD-L1 IgG4 antibody sugemalimab resulted in a response for nearly half of patients and a complete response in one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.

Rolling Submission of BLA to FDA Completed for Omidubicel in Blood Cancers Requiring Transplant

June 2nd 2022

The rolling biologics license application submission to the FDA to support the approval of omidubicel for patients with blood cancers in need of allogenic hematopoietic stem cell transplant has been completed.

Selecting the Right Patients for CPX-351 or Venetoclax + Azacitidine in AML

June 2nd 2022

Richard Stone, MD, and Eunice Wang, MD, provide an overview of how patients with AML are selected for treatment with CPX-351 or the combination of venetoclax-azacitidine.

CPX-351 in Treatment of AML and Clinical Considerations

June 2nd 2022

Richard Stone, MD, and Eunice Wang, MD, comment on the role of CPX-351 in the treatment of secondary AML and offer practice pointers for treatment with this drug, including management of adverse events.

FDA Withdraws Approvals for Umbralisib in MZL, Follicular Lymphoma Due to Safety Concerns

June 1st 2022

The FDA announced that it has withdrawn approval for umbralisib, an oral inhibitor of PI3K-δ and CK1-ε manufactured by TG Therapeutics.

Dr. Sallman on the Novel Menin Inhibitor KO-539 in AML

May 31st 2022

David Sallman, MD, discusses the background of the menin inhibitor, KO-539, in acute myeloid leukemia.

Sorafenib Plus Standard Chemotherapy Provides Clinical Benefit in Pediatric FLT3-ITD+ AML

May 30th 2022

The addition of sorafenib to conventional chemotherapy was safe and demonstrated evidence of improved outcomes in pediatric patients with FLT3-ITD–positive acute myeloid leukemia.

FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma

May 27th 2022

The FDA has granted accelerated approval to tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

Zanubrutinib Approved in Uruguay for MCL, MZL, and Waldenström Macroglobulinemia

May 27th 2022

The BTK inhibitor zanubrutinib has been approved in Uruguay for the treatment of adult patients with previously treated mantle cell lymphoma, relapsed or refractory marginal zone lymphoma, and Waldenström macroglobulinemia.

Patient Profile 1: Patient with Secondary Acute Myeloid Leukemia

May 26th 2022

Two experts review a patient profile and discuss whether the patient meets the criteria for secondary acute myeloid leukemia (AML).

Secondary Acute Myeloid Leukemia (AML): Overview

May 26th 2022

Richard Stone, MD, and Eunice Wang, MD, define secondary acute myeloid leukemia treatment goals and how treatment has been affected by the COVID-19 pandemic.

FDA Approves Ivosidenib Plus Azacitidine for Newly Diagnosed IDH1-Mutated AML

May 25th 2022

The FDA has approved ivosidenib (Tibsovo) in combination with azacitidine for the treatment of patients with newly diagnosed IDH1-mutated acute myeloid leukemia who are aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

FDA Lifts Partial Clinical Hold on NEON-2 Trial Evaluating Davoceticept Plus Pembrolizumab in Advanced Malignancies

May 24th 2022

The FDA has lifted a partial clinical hold on the phase 1 NEON-2 trial investigating the use of davoceticept in combination with pembrolizumab in adult patients with advanced solid tumors or lymphoma.

FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia

May 20th 2022

The FDA has approved azacitidine (Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.

Dr. Ailawadhi on the Examination of Iopofosine I-131 in Waldenström Macroglobulinemia

May 20th 2022

Sikander Ailawadhi, MD, discusses the examination of iopofosine I-131 (CLR 131) in Waldenström macroglobulinemia.

FDA Places Partial Clinical Hold on Phase 1 Trial Evaluating FHD-286 in Relapsed/Refractory AML and MDS

May 20th 2022

The FDA has placed a partial clinical hold on a phase 1 trial investigating FHD-286 as a treatment for patients with relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome.

Dr. Lenz on the European Approval of Liso-cel in Relapsed/Refractory LBCL

May 20th 2022

Georg Lenz, MD, discussed the European approval of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

Pro Presents Interim Results of PRIMO in Peripheral T-Cell Lymphoma

May 19th 2022

Dr Pro outlines the current role of duvelisib in peripheral T-cell lymphoma (PTCL), reviews some key adverse effects associated with the agent, and walks us through other important updates in PTCL presented at the 2021 ASH Annual Meeting and Exposition.

Trial Assessing CAR T-Cell Therapy ACLX-001 in Relapsed/Refractory Multiple Myeloma Begins

May 19th 2022

Investigators have initiated a phase 1 trial exploring ACLX-001, a novel CAR T-cell therapy using the ARC-SparX platform, in patients with relapsed/refractory multiple myeloma.